

OPEN

# A Patient With Metastatic Sarcoma was Successfully Treated With Radiolabeled Somatostatin Analogs

Aurora Crespo-Jara, MD,\* Ramón González Manzano, MD, PhD,\* Maribel Lopera Sierra, MD,†  
 María Carmen Redal Peña, MD,\* and Antonio Brugarolas Masllorens, MD, PhD\*

**Abstract:** We present a sarcoma patient with a tumor reduction of more than 50% in lung metastasis after 2 single courses of the investigational medical product Lutathera ( $^{177}\text{Lu}$ -DOTA0-Tyr3-octreotate). She was resistant to more than 6 lines of therapy including all the available active drugs in soft tissue sarcomas. The high expression of somatostatin receptors was shown by microarrays and Octreoscan. The overall duration of response exceeded 1 year.

**Key Words:** microarray expression, Octreoscan, peptide receptor radionuclide therapy, radiolabeled somatostatin analogs, sarcoma, somatostatin receptors, synovial sarcoma

(*Clin Nucl Med* 2016;41: 705–707)

Received for publication February 1, 2016; revision accepted May 1, 2016.

From the \*Plataforma de Oncología Hospital Quirón Torre Vieja, Cátedra Oncología Multidisciplinar Universidad Católica San Antonio de Murcia, Murcia, Spain; and †Advanced Accelerator Applications, New York, NY.

Conflicts of interest and sources of funding: none declared.

Correspondence to: Aurora Crespo-Jara, MD, Plataforma de Oncología, Hospital Quirónsalud Torre Vieja, Partida de la Loma s/n 03184 Torre Vieja, Alicante, Spain. E-mail: aurora.crespo@quironsalud.es.

Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved. This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND), where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially.

ISSN: 0363-9762/16/4109-0705

DOI: 10.1097/RLU.0000000000001288

## REFERENCES

1. Florio T, Montella L, Corsaro A, et al. In vitro and in vivo expression of somatostatin receptors in intermediate and malignant soft tissue tumors. *Anticancer Res*. 2003;23:2465–2471.
2. Rebollo J, Sureda M, Martínez EM, et al. Gene expression profiling of tumors from heavily pretreated patients with metastatic cancer for the selection of therapy: a pilot study. *Am J Clin Oncol*. 2014. [Epub ahead of print].
3. Friedberg JW, Van den Abbeele AD, Kehoe K, et al. Uptake of radiolabeled somatostatin analog is detectable in patients with metastatic foci of sarcoma. *Cancer*. 1999;86:1621–1627.
4. Giannakenas C, Kalofonos HP, Apostolopoulos D, et al. Scintigraphic imaging of sarcomatous tumors with [(111)In-DTPA-Phe-1]-octreotide. *Oncology*. 2000;58:18–24.
5. Kwekkeboom DJ, De Herder WW, Kam BL, et al. Treatment with the radiolabeled somatostatin analog [ $^{177}\text{Lu}$ -DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival. *J Clin Oncol*. 2008;26:2124–2130.
6. Teunissen J, Kwekkeboom D, Krenning E. Quality of life in patients with gastroenteropancreatic tumors treated with [ $^{177}\text{Lu}$ -DOTA0,Tyr3]octreotate. *J Clin Oncol*. 2004;22:2724–2729.
7. Bodei L, Cremonesi M, Grana CM, et al. Peptide receptor radionuclide therapy with  $^{177}\text{Lu}$ -DOTATATE: the IEO phase I-II study. *Eur J Nucl Med Mol Imaging*. 2011;38:2125–2135.
8. Bodei L, Kidd M, Paganelli G, et al. Long-term tolerability of PRRT in 807 patients with neuroendocrine tumours: the value and limitations of clinical factors. *Eur J Nucl Med Mol Imaging*. 2015;42:5–19.
9. Garkavij M, Nickel M, Sjögreen-Gleisner K, et al.  $^{177}\text{Lu}$ -[DOTA0,Tyr3]octreotate therapy in patients with disseminated neuroendocrine tumors: analysis of dosimetry with impact on future therapeutic strategy. *Cancer*. 2010;116:1084–1092.